The Pistoia Alliance announced key trends for the life science industry in 2019 based on The Life Sciences Innovation Report developed with Clarivate Analytics.

Key report findings include:

  • Innovation is being driven via collaboration from multiple industry stakeholders: The emergence and development of new tools like nanosensors, bi-specific antibodies, and computational biology have highlighted the success that can be achieved from collaboration between researchers and organizations across a range of disciplines. This trend will continue in 2019.
  • Technologies are being adopted to advance drug research: The report findings show budgets will continue to increase to allow for new technological advances, including the use of artificial intelligence in R&D decision making. Research from The Pistoia Alliance has already shown growth in the implementation of AI and blockchain.
  • New types of research are coming to the forefront: Research in precision medicine, immunotherapy, and the microbiome are opening up new discovery pathways. Alongside genomic research, these new approaches will provide a more refined understanding of diseases, better diagnoses, and improvements to treatment.
  • Digitization of R&D and healthcare will increase: R&D functions are already beginning to adopt large-scale use of cloud-based platforms, but this will accelerate this year. Mobile computing is poised to support the digitization of health in combination with drug therapy, as well as through stand-alone therapies.
  • Academia is increasingly contributing to biologics R&D: Academia has already made significant contributions to scientific innovation across genetic and cellular therapies, with antibodies, CAR-T, and CRISPR-Cas9 all leading to new approaches to potential novel biological therapies. The role of academia will become more vital as researchers look to expand on existing research.

Members of The Pistoia Alliance helped create the report, which includes analysis by Cortellis, a suite of intelligence solutions for drug development and commercialization provided by Clarivate Analytics. Key contributors include executives from life science organizations such as Cancer Research UK, GlaxoSmithKline, AbbVie, and Diavics.

The main theme of all emerging trends for 2019 is the continuing need for greater cross-industry collaboration to realize the potential in these areas, according to the report.

“The life sciences industry is at a real crossroads: heightened global competition, tougher regulatory standards, and continued cost pressures make efficient innovation in R&D more imperative than ever,” said Christopher McKenna, global head of life sciences professional services & consulting at Clarivate Analytics and co-author of the report.

“I’m encouraged by what our analysis reveals. Cross-stakeholder collaboration, new digital technologies and therapeutic approaches, and the role of cloud-based computing, among others, are having a dramatic impact on drug and device development. This will continue to expand in 2019 and beyond, enabling more novel therapies to reach the market with the advancement of more permanent efficacy for patients.”

The Life Sciences Innovation Report can be found at:

Previous articleTraditional Approaches for Company Valuation Are Flawed for Valuing In Vivo Gene Therapy Companies
Next articleGene Drive Alternative Could Lead Pesky Insects to Dead Ends